X-linked hypophosphatemia, or XLH, is a hereditary skeletal disease triggered by excess production of the hormone fibroblast growth factor 23. FGF23 causes phosphate urinary excretion and hinders patients' ability to produce vitamin D. CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
The global Crysvita Injection market was valued at US$ 68 million in 2023 and is anticipated to reach US$ 85 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
Brosumab (burosumab, trade name Crysvita) is a recombinant fully humanized monoclonal IgG1 antibody targeting fibroblast growth factor 23 (FGF23) jointly developed by Ultragenyx Pharmaceutical and Kyowa Hakko Kirin. In February 2018, the drug was conditionally approved by the European Union for the treatment of X-linked hypophosphatemia (XLH) in children and adults aged 1 and above, becoming the world's first XLH treatment drug, and it was approved by the FDA in April of the same year indications. In September of the following year, the drug was approved by the FDA to expand the indication population to infants as young as 6 months old. FGF23 is a bone-derived hormone that regulates the metabolism of phosphorus and vitamin D. It can block the reabsorption of phosphate by the kidney and inhibit the absorption of vitamin D-dependent phosphate, resulting in a significant decrease in the level of phosphate in the blood. It is XLH main culprit. XLH is a rare genetic disorder and the most common form of hypophosphatemic rickets, affecting 1 in 20,000 people. XLH is carried on the X chromosome, and while nearly all X-linked disorders are recessive, XLH is one of the few that is inherited in a dominant manner.
This report aims to provide a comprehensive presentation of the global market for Crysvita Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Crysvita Injection.
Report Scope
The Crysvita Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Crysvita Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Crysvita Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Kyowa Kirin
Ultragenyx Pharmaceutical
Segment by Type
10 mg/mL
20 mg/mL
30 mg/mL
Segment by Application
Children
Adults
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Crysvita Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Crysvita Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Crysvita Injection Market Overview
1.1 Product Overview and Scope of Crysvita Injection
1.2 Crysvita Injection Segment by Type
1.2.1 Global Crysvita Injection Market Value Comparison by Type (2024-2030)
1.2.2 10 mg/mL
1.2.3 20 mg/mL
1.2.4 30 mg/mL
1.3 Crysvita Injection Segment by Application
1.3.1 Global Crysvita Injection Market Value by Application: (2024-2030)
1.3.2 Children
1.3.3 Adults
1.4 Global Crysvita Injection Market Size Estimates and Forecasts
1.4.1 Global Crysvita Injection Revenue 2019-2030
1.4.2 Global Crysvita Injection Sales 2019-2030
1.4.3 Global Crysvita Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Crysvita Injection Market Competition by Manufacturers
2.1 Global Crysvita Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global Crysvita Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Crysvita Injection Average Price by Manufacturers (2019-2024)
2.4 Global Crysvita Injection Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Crysvita Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Crysvita Injection, Product Type & Application
2.7 Crysvita Injection Market Competitive Situation and Trends
2.7.1 Crysvita Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Crysvita Injection Players Market Share by Revenue
2.7.3 Global Crysvita Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Crysvita Injection Retrospective Market Scenario by Region
3.1 Global Crysvita Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Crysvita Injection Global Crysvita Injection Sales by Region: 2019-2030
3.2.1 Global Crysvita Injection Sales by Region: 2019-2024
3.2.2 Global Crysvita Injection Sales by Region: 2025-2030
3.3 Global Crysvita Injection Global Crysvita Injection Revenue by Region: 2019-2030
3.3.1 Global Crysvita Injection Revenue by Region: 2019-2024
3.3.2 Global Crysvita Injection Revenue by Region: 2025-2030
3.4 North America Crysvita Injection Market Facts & Figures by Country
3.4.1 North America Crysvita Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Crysvita Injection Sales by Country (2019-2030)
3.4.3 North America Crysvita Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Crysvita Injection Market Facts & Figures by Country
3.5.1 Europe Crysvita Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Crysvita Injection Sales by Country (2019-2030)
3.5.3 Europe Crysvita Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Crysvita Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Crysvita Injection Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Crysvita Injection Sales by Country (2019-2030)
3.6.3 Asia Pacific Crysvita Injection Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Crysvita Injection Market Facts & Figures by Country
3.7.1 Latin America Crysvita Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Crysvita Injection Sales by Country (2019-2030)
3.7.3 Latin America Crysvita Injection Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Crysvita Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Crysvita Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Crysvita Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Crysvita Injection Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Crysvita Injection Sales by Type (2019-2030)
4.1.1 Global Crysvita Injection Sales by Type (2019-2024)
4.1.2 Global Crysvita Injection Sales by Type (2025-2030)
4.1.3 Global Crysvita Injection Sales Market Share by Type (2019-2030)
4.2 Global Crysvita Injection Revenue by Type (2019-2030)
4.2.1 Global Crysvita Injection Revenue by Type (2019-2024)
4.2.2 Global Crysvita Injection Revenue by Type (2025-2030)
4.2.3 Global Crysvita Injection Revenue Market Share by Type (2019-2030)
4.3 Global Crysvita Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Crysvita Injection Sales by Application (2019-2030)
5.1.1 Global Crysvita Injection Sales by Application (2019-2024)
5.1.2 Global Crysvita Injection Sales by Application (2025-2030)
5.1.3 Global Crysvita Injection Sales Market Share by Application (2019-2030)
5.2 Global Crysvita Injection Revenue by Application (2019-2030)
5.2.1 Global Crysvita Injection Revenue by Application (2019-2024)
5.2.2 Global Crysvita Injection Revenue by Application (2025-2030)
5.2.3 Global Crysvita Injection Revenue Market Share by Application (2019-2030)
5.3 Global Crysvita Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Kyowa Kirin
6.1.1 Kyowa Kirin Corporation Information
6.1.2 Kyowa Kirin Description and Business Overview
6.1.3 Kyowa Kirin Crysvita Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Kyowa Kirin Crysvita Injection Product Portfolio
6.1.5 Kyowa Kirin Recent Developments/Updates
6.2 Ultragenyx Pharmaceutical
6.2.1 Ultragenyx Pharmaceutical Corporation Information
6.2.2 Ultragenyx Pharmaceutical Description and Business Overview
6.2.3 Ultragenyx Pharmaceutical Crysvita Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ultragenyx Pharmaceutical Crysvita Injection Product Portfolio
6.2.5 Ultragenyx Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Crysvita Injection Industry Chain Analysis
7.2 Crysvita Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Crysvita Injection Production Mode & Process
7.4 Crysvita Injection Sales and Marketing
7.4.1 Crysvita Injection Sales Channels
7.4.2 Crysvita Injection Distributors
7.5 Crysvita Injection Customers
8 Crysvita Injection Market Dynamics
8.1 Crysvita Injection Industry Trends
8.2 Crysvita Injection Market Drivers
8.3 Crysvita Injection Market Challenges
8.4 Crysvita Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Kyowa Kirin
Ultragenyx Pharmaceutical
*If Applicable.